13 In 1993, The Journal of Clinical Apheresis published a paper detailing the use of TPE as either a first- or second-line therapy to be used with other modalities on disorders such as Raynauds disease, systemic lupus erythematosus, coagulation factor inhibitors, familial hypercholesterolemia, acute Guillain-Barr syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, cryoglobulinemia, Goodpastures syndrome, and thrombotic thrombocytopenic purpura
Obesity and Weight Management: The obesity and weight management segment is anticipated to grow at the fastest rate, fueled by the rising number of obese individuals and the demand for effective weight management solutions
2019;11(12) doi: 10.3390/nu11122971
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
KN content was effectively higher in ChT (+ 175%), ChT + amlodipine (+ 120%), ChT + aminoguanidine (+ 111%), and ChT + NAC (+ 116%) than BSA (Fig